{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":12,"description":"VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"EG000","otherNumAffected":9,"otherNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"title":"Grade 2-3 Established Neuropathy"},{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"EG001","otherNumAffected":2,"otherNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"title":"Grade 1-2 New-onset Neuropathy"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":11,"numEvents":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0}],"term":"Pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":11,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0}],"term":"Arthritis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":11,"numEvents":2},{"groupId":"EG001","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Muscle cramp"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":11,"numEvents":5},{"groupId":"EG001","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Pain in extremity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":11,"numEvents":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0}],"term":"Dysesthesia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":11,"numEvents":7},{"groupId":"EG001","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Paresthesia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":11,"numEvents":7},{"groupId":"EG001","numAffected":1,"numAtRisk":6,"numEvents":2}],"term":"Peripheral sensory neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0}],"term":"Insomnia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 5","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":6,"numEvents":0}],"term":"Pruritus"}],"timeFrame":"Adverse events were collected at initiation of treatment (day 0, week 1), at week 4, and week 8 visits. One enrolled participant was never treated and no adverse event data was collected on that participant, but that participant was followed for all cause mortality."}